Baker Brothers Life Sciences LP is Director & 10% Owner at GENOMIC HEALTH INC (GHDX). They have made 50 open-market trades across 13 companies since 2012, most recently 2025-12-18.
CIK 0001363364
34 open-market purchases totalling $1.5B since 2012, against 16 sales. Across 34 scored buys the stock is up 15.8% at ninety days, and 12.4 points ahead of the S&P over the same stretch.
34 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 56% | 62% | 65% |
| Avg Move | -2.3% | +7.4% | +15.8% |
| Alpha | -2.3% | +6.0% | +12.4% |
| Scored | 34 | 34 | 34 |
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 88% | 87% | 80% |
| Avg Move | -6.4% | -10.6% | -14.5% |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| KOD | BUY | 2025-12-18 | 2025-12-19 | $23.00 | $60.0M | -6.9% | -4.7% | -18.9% |
| BGNE | SELL | 2024-12-09 | 2024-12-10 | $187.98 | $201.9M | -5.6% | N/A | N/A |
| IGMS | BUY | 2023-12-13 | 2023-12-15 | $6.41 | $5.4M | +22.1% | +32.4% | +41.7% |
| MDGL | BUY | 2023-11-17 | 2023-11-21 | $177.85 | $22.1M | +15.4% | +15.6% | +19.4% |
| BGNE | SELL | 2023-11-14 | 2023-11-14 | $180.50 | $198.6M | -8.6% | -6.3% | -26.8% |
| NLTX | BUY | 2023-08-15 | 2023-08-17 | $0.64 | $2.9M | -9.0% | -1.3% | -11.5% |
| KOD | BUY | 2022-05-16 | 2022-05-18 | $5.91 | $5.3M | +11.4% | +21.7% | +81.7% |
| KOD | BUY | 2022-02-15 | 2022-02-17 | $54.45 | $43.6M | -83.8% | -84.9% | -89.0% |
| SGEN | SELL | 2021-11-30 | 2021-12-02 | $160.76 | $90.3M | -8.9% | -0.5% | -20.2% |
| KOD | BUY | 2021-09-15 | 2021-09-17 | $94.39 | $6.0M | -3.4% | +10.7% | -19.9% |
| KOD | BUY | 2021-06-28 | 2021-06-30 | $91.39 | $33.4M | -2.0% | -11.8% | +5.7% |
| KOD | BUY | 2020-11-20 | 2020-11-24 | $108.00 | $165.0M | +0.8% | +24.6% | -0.8% |
| KOD | BUY | 2020-09-22 | 2020-09-24 | $51.71 | $20.9M | +17.8% | +77.0% | +180.8% |
| SGEN | SELL | 2020-05-15 | 2020-05-19 | $160.00 | $280.0M | +0.4% | +1.0% | +2.2% |
| ACAD | BUY | 2019-09-20 | 2019-09-20 | $40.00 | $62.5M | -11.4% | +2.5% | +3.4% |
| GHDX | SELL | 2019-03-14 | 2019-03-14 | $76.49 | $4.9M | -6.3% | -14.4% | -31.5% |
| GHDX | SELL | 2019-03-14 | 2019-03-14 | $76.48 | $4.3M | -6.3% | -14.4% | -31.5% |
| GHDX | SELL | 2019-03-13 | 2019-03-14 | $75.92 | $6.0M | -6.3% | -14.4% | -31.5% |
| GHDX | SELL | 2019-03-12 | 2019-03-14 | $75.78 | $11.7M | -6.3% | -14.4% | -31.5% |
| GHDX | SELL | 2019-03-12 | 2019-03-14 | $75.63 | $5.6M | -6.3% | -14.4% | -31.5% |
| GHDX | SELL | 2019-01-28 | 2019-01-30 | $71.07 | $6.4M | +7.8% | +3.2% | -13.8% |
| GHDX | SELL | 2018-11-30 | 2018-12-03 | $79.20 | $16.2M | -9.7% | -19.0% | -0.4% |
| GHDX | SELL | 2018-11-29 | 2018-12-03 | $78.95 | $20.2M | -9.7% | -19.0% | -0.4% |
| GHDX | SELL | 2018-11-29 | 2018-12-03 | $77.94 | $3.9M | -9.7% | -19.0% | -0.4% |
| GHDX | SELL | 2018-11-09 | 2018-11-13 | $83.79 | $8.1M | -2.4% | -8.1% | +5.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.
| ACAD | 3,383,621 | $64.7M |
| ONC | 148,069 | $54.7M |
| IDRA | 4,132,528 | $29.9M |
| GHDX | 175,688 | $11.1M |
| KNSA | 128,802 | $10.1M |
| NLTX | 481,416 | $6.7M |
| IGMS | 355,142 | $451K |
| Total | $14.7B |
Shares reported on the most recent Form 4, priced at the 2025-12-19 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Scored | 16 | 15 | 15 |